Increasing Long-Term Survival In Patients With Severe Liver Cancer

Main Category: Liver Disease / Hepatitis
Also Included In: Cancer / Oncology;  Radiology / Nuclear Medicine;  Transplants / Organ Donations
Article Date: 23 Nov 2009 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (2 votes)

Healthcare Prof:4 stars

4 (1 votes)


In patients with unresectable (unable to be removed by surgery) liver cancer, an interventional radiology procedure called triple-drug transcatheter arterial chemoemobolization (TACE) followed by a liver transplant may significantly increase a patient's chance of long-term survival, according to a study published in the December issue of the American Journal of Roentgenology.

Liver cancer is the fourth most common cancer in the world and is responsible for more than 500,000 deaths worldwide annually. During triple-drug TACE, anti-cancer drugs are injected directly into the blood vessel feeding a cancerous tumor. An embolic agent is placed inside the blood vessels that supply blood to the tumor, in effect trapping the chemotherapy in the tumor.

The study, performed at the David Geffen UCLA School of Medicine in Los Angeles, included 124 patients with unresectable liver cancer. Twenty-eight patients underwent triple-drug TACE followed by a liver transplantation; 96 patients underwent triple-drug TACE only. "In our study, patients who underwent triple-drug TACE followed by liver transplantation showed the longest survival," said Antoinette S. Gomes, M.D., lead author of the study. The median survival in the transplant recipient group was 112.80 months. In the no-transplant group, the median survival was 15.75 months.

"Until recently, there has been considerable controversy regarding the benefits of emobolization therapy in patients with unresectable liver cancer," said Gomes.

"In our series, survival after TACE was best in patients who ultimately underwent liver transplantation. However triple-drug TACE alone still improved survival in patients who did not undergo a liver transplantation," she said.

Source: Heather Curry
American College of Radiology / American Roentgen Ray Society

Article adapted by Medical News Today from original press release.
Visit our liver disease / hepatitis section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Heather Curry. "Increasing Long-Term Survival In Patients With Severe Liver Cancer." Medical News Today. MediLexicon, Intl., 23 Nov. 2009. Web.
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/171837.php>

APA
Heather Curry. (2009, November 23). "Increasing Long-Term Survival In Patients With Severe Liver Cancer." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/171837.php.

Please note: If no author information is provided, the source is cited instead.


Liver Disease / Hepatitis

Most Popular Articles



Follow Our Liver Disease News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Liver Disease / Hepatitis Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »